Skip to main content
. 2019 Mar 12;105(9):1256–1262. doi: 10.1136/bjophthalmol-2018-312767

Figure 3.

Figure 3

General quality of life and visual quality of life Mean change in General QoL (SF36)* and Visual QoL* (VCM1) scores from the baseline visit to each year of treatment on either adalimumab or infliximab. (A) SF36 mental component, (B) SF36 physical component and (C) VCM1 Visual QoL. (N indicates the number of participants for each year of treatment. Error bars represent the standard error. For SF36, a positive change indicates improvement of QoL. For VCM, a negative change indicates improvement of visual QoL. *The SF36 summarises 8 dimensions of general health into a Physical Component Score (PCS) and a Mental Component score (MCS), ranging from 0 to 100 (best score).12 The VCM1 is a 10 point visual QoL which captures patient–reported measures of visual health on emotional, physical, social and psychological aspects of visual quality of life.8 13 14 23